Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Astrazeneca Plc ADR 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS CAMBRIDGE X0 CB2 0AA GBR

www.astrazeneca.com Employees: 94,300 P: 44-20-3749-5000 F: 122-335-2858

Sector:

Medical

Description:

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.

Key Statistics

Overview:

Market Capitalization, $K 216,125,920
Enterprise Value, $K 239,480,928
Shares Outstanding, K 3,101,247
Annual Sales, $ 54,073 M
Annual Net Income, $ 7,035 M
Last Quarter Sales, $ 13,588 M
Last Quarter Net Income, $ 2,921 M
EBIT, $ 10,562 M
EBITDA, $ 17,250 M
60-Month Beta 0.40
% of Institutional Shareholders 20.35%
Float, K 3,101,247
% Float 100.00%
Short Volume Ratio 0.26

Growth:

1-Year Return -9.32%
3-Year Return 3.40%
5-Year Return 27.64%
5-Year Revenue Growth 121.76%
5-Year Earnings Growth 134.86%
5-Year Dividend Growth 6.57%

Per-Share Information:

Most Recent Earnings 1.24 on 04/29/25
Next Earnings Date N/A
Earnings Per Share ttm 4.32
EPS Growth vs. Prev Qtr 18.10%
EPS Growth vs. Prev Year 20.39%
Annual Dividend Rate, $ 1.52
Annual Dividend Yield 2.18%
Most Recent Dividend 1.030 on 02/21/25
Next Ex-Dividends Date 02/21/25
Dividend Payable Date 03/24/25
Dividend Payout Ratio 35.03%
Most Recent Split 2-1 on 07/27/15

AZN Ratios

Ratio
Price/Earnings ttm 15.93
Price/Earnings forward 15.30
Price/Earnings to Growth 1.26
Return-on-Equity % 33.14%
Return-on-Assets % 12.83%
Profit Margin % 13.01%
Debt/Equity 0.73
Price/Sales 3.95
Price/Cash Flow 10.93
Price/Book 5.19
Book Value/Share 13.26
Interest Coverage 5.99

AZN Dividends

Date Value
02/21/25 $1.0300
08/09/24 $0.4900
02/22/24 $0.9650
08/10/23 $0.4550
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »